Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 6.9% – Time to Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price fell 6.9% during mid-day trading on Monday . The stock traded as low as $6.01 and last traded at $6.14. 8,113,213 shares traded hands during trading, a decline of 68% from the average session volume of 25,409,162 shares. The stock had previously closed at $6.59.

Wall Street Analyst Weigh In

Several research firms recently commented on RXRX. Leerink Partners reduced their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Friday, February 28th. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. KeyCorp dropped their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $8.25.

Recursion Pharmaceuticals Trading Down 1.1 %

The stock’s fifty day moving average price is $7.61 and its two-hundred day moving average price is $7.05. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $2.44 billion, a P/E ratio of -3.96 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same period last year, the firm posted ($0.42) EPS. The company’s revenue was down 57.8% on a year-over-year basis. Equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Decker Retirement Planning Inc. bought a new stake in Recursion Pharmaceuticals in the 4th quarter worth $26,000. Private Trust Co. NA purchased a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth about $27,000. GAMMA Investing LLC grew its stake in shares of Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after purchasing an additional 4,091 shares during the period. Finally, KBC Group NV raised its position in Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after purchasing an additional 3,377 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.